Going concern
Filing comparison
Aligos Therapeutics, Inc. disclosed substantial doubt about its ability to continue as a going concern
No going-concern disclosure → Substantial doubt about ability to continue as a going concern
Going concern As of December 31, 2025 and December 31, 2024, we had an accumulated deficit of $642.2 million and $618.0 million, respectively, and cash, cash equivalents and short-term investments of $77.8 million and $56.9 million, respectively. Our current operating plan and projected cash outflows for the upcoming periods raise doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Annual Report. We plan to raise additional capital to fund continued operations beyond the third quarter of 2026.…
Evidence
- Blank check
- No
- Comparable
- Yes
- Current state
- substantial_doubt
- Current state label
- Substantial doubt about ability to continue as a going concern
- Direction
- escalated
- Located in
- going-concern note
- Prior filed
- 2025-03-10
- Prior form
- 10-K
- Prior state
- none
- Prior state label
- No going-concern disclosure
- Source
- ASC 205-40 going-concern note comparison
- Why
- Disclosure about the company's ability to continue as a going concern changed compared with its previous report.